A prospective randomized comparison of cefotaxime vs ampicillin and chloramphenicol for bacterial meningitis in...

Area of Science:

• Pediatric Infectious Diseases
• Bacterial Meningitis Treatment
• Antibiotic Efficacy

Background:

• Bacterial meningitis remains a significant cause of childhood morbidity and mortality.
• Antibiotic resistance, particularly to ampicillin in Haemophilus influenzae, poses a challenge in treatment.
• Evaluating novel antibiotic regimens is crucial for improving patient outcomes.

Purpose of the Study:

• To compare the efficacy and safety of cefotaxime versus standard therapy (ampicillin and chloramphenicol) in treating bacterial meningitis in children.
• To assess clinical cure rates, survival without sequelae, and duration of therapy.
• To identify the susceptibility patterns of common bacterial meningitis pathogens to cefotaxime.

Main Methods:

• Prospective randomized trial involving 50 children diagnosed with bacterial meningitis.
• Patients were assigned to receive either cefotaxime or standard ampicillin and chloramphenicol therapy.
• Bacterial isolates were identified, and antibiotic susceptibility testing was performed.

Main Results:

• All bacterial isolates, including ampicillin-resistant Haemophilus influenzae, were susceptible to cefotaxime.
• Clinical cure rates were high and similar in both groups (100% for cefotaxime vs. 96% for standard therapy).
• Survival without sequelae (78% vs. 77%) and defervescence times were comparable, with no adverse events reported.

Conclusions:

• Cefotaxime is as safe and effective as standard antibiotic therapy for pediatric bacterial meningitis.
• The study supports the use of cefotaxime in managing bacterial meningitis, especially in areas with high rates of ampicillin resistance.
• Further research may explore broader applications of cefotaxime in pediatric infections.